Long-Term Treatment With Eicosapentaenoic Acid Ameliorates Myocardial Ischemia-Reperfusion Injury in Pigs In Vivo - Involvement of Rho-Kinase Pathway Inhibition -

Gao, Jun; Yasuda, Satoshi; Tsuburaya, Ryuji; Ito, Yoshitaka; Shiroto, Takashi; Hao, Kun; Aizawa, Katsuo; Kikuchi, Yoku; Ito, Kei; Shimokawa, Hiroaki

doi:10.1253/circj.cj-11-0209

Cited by 20 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Omega-3 PUFA administration has also been shown to confer protection against hepatic (Kim et al 2013), renal (Ashtiyani et al 2012), intestinal (Arisue et al 2012, Brahmbhatt et al 2013, cerebral (Pan et al 2009), pulmonary (Lee et al 2008), and myocardial (ZeghichiHamri et al 2010, Gao et al 2011) IR injury.…”

Section: Discussionmentioning

confidence: 99%

Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia–reperfusion injury

Jones¹,

Mark²,

Waddell³

2013

Reproduction

View full text Add to dashboard Cite

Placental oxidative stress plays a key role in the pathophysiology of several placenta-related disorders. Oxidative stress occurs when excess reactive oxygen species (ROS) damages cellular components, an outcome limited by antioxidant enzymes; mitochondrial uncoupling protein 2 (UCP2) also limits ROS production. We recently reported that maternal dietary omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation reduced placental oxidative damage and enhanced fetal and placental growth in the rats. Here, we examined the effect of n-3 PUFAs on placental antioxidant defences and whether n-3 PUFA supplementation could prevent growth restriction induced by placental ischaemia-reperfusion (IR), a known inducer of oxidative stress. Rats were fed either standard or high-n-3 PUFA diets from day 1 of pregnancy. Placentas were collected on days 17 and 22 in untreated pregnancies (termZday 23) and at day 22 following IR treatment on day 17. Expression of several antioxidant enzyme genes (Sod1, Sod2, Sod3, Cat, Txn1 and Gpx3) and Ucp2 was measured by quantitative RT-PCR in the placental labyrinth zone (LZ) and junctional zone (JZ). Cytosolic superoxide dismutase (SOD), mitochondrial SOD and catalase (CAT) activities were also analyzed. Maternal n-3 PUFA supplementation increased LZ mRNA expression of Cat at both gestational days (2-and 1.5-fold respectively; P!0.01) and female Sod2 at day 22 (1.4-fold, P!0.01). Cytosolic SOD activity increased with n-3 PUFA supplementation at day 22 (1.3-fold, P!0.05). Sod1 and Txn1 expression decreased marginally (30 and 22%, P!0.05). JZ antioxidant defences were largely unaffected by diet. Despite increased LZ antioxidant defences, maternal n-3 PUFA supplementation did not protect against placental IR-induced growth restriction of the fetus and placental LZ.

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia–reperfusion injury

Jones¹,

Mark²,

Waddell³

2013

Reproduction

View full text Add to dashboard Cite

show abstract

“…15,16 It has been recently demonstrated that long-term treatment with EPA significantly inhibits Rho-kinase activation in the myocardium subjected to ischaemia-reperfusion in vivo ( Figure 2). 17 In addition, supplementation with EPA and DHA could exert a protective effect on the heart through improvement in mitochondrial function and the efficiency of ATP generation. 18 This effect may be due to changes in mitochondrial membrane phospholipids composition and improved efficiency of ATP generation.…”

Section: Anti-inflammatory Effectsmentioning

confidence: 99%

Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?

Kromhout

Yasuda

Geleijnse

et al. 2011

European Heart Journal

205

157

View full text Add to dashboard Cite

Omega-3 fatty acids, which are found abundantly in fish oil, exert pleiotropic cardiometabolic effects with a diverse range of actions. The results of previous studies raised a lot of interest in the role of fish oil and omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases. The present review will focus on the current clinical uses of omega-3 fatty acids and provide an update on their effects. Since recently published trials in patients with coronary artery diseases or post-myocardial infarction did not show an effect of omega-3 fatty acids on major cardiovascular endpoints, this review will examine the limitations of those data and suggest recommendations for the use of omega-3 fatty acids.

show abstract

“…In IP-deficient mice, the size of the myocardial infarction caused by coronary artery ligation is significantly increased compared to that observed in wild-type mice, suggesting that PGI2 protects the myocardium from ischemia and reperfusion injury 88) . Meanwhile, the administration of hp-EPA-E (Epadel ® ) reduces neutrophil infiltration in ischemic regions caused by myocardial ischemia following left circumflex coronary artery ligation and reperfusion in pigs, thus helping to maintain the myocardial eNOS activity in the ischemic myocardium 89) . EPA is thought to exert its anti-ischemic heart disease actions via PGI3.…”

Section: Pgi2 and Pgi3 In Ischemic Heart Diseasementioning

confidence: 99%

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Ohnishi

Saitō

2013

JAT

View full text Add to dashboard Cite

The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treating cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsaturated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Intervention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher levels of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was ＞0.75. Furthermore, the ratio of prostaglandin (

show abstract

Long-Term Treatment With Eicosapentaenoic Acid Ameliorates Myocardial Ischemia-Reperfusion Injury in Pigs In Vivo - Involvement of Rho-Kinase Pathway Inhibition -

Cited by 20 publications

References 52 publications

Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia–reperfusion injury

Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia–reperfusion injury

Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Contact Info

Product

Resources

About